The SEC concluded that Cassava Sciences falsified data in its Alzheimer’s clinical trials. Now the FDA needs to act, ...

Key Takeaways Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC.The ...

Eli Lilly will invest $4.5 billion to create the Lilly Medicine Foundry, which the drug giant says will be the first-ever ...

Before market open, Cassava announced that it has reached agreement with the U.S. Securities and Exchange Commission (SEC) to ...

The SEC has fined Cassava Sciences $40 million for misleading investors on the company's Alzheimer's drug candidate simufilam ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...

In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $1.29 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...

The Securities & Exchange Commission (SEC) has accused Cassava's founder and former chief executive Remi Barbier and former ...

The scrutiny follows allegations of data manipulation and misleading claims about the drug's effectiveness, leading the Securities and Exchange Commission to charge the company, which resulted in a ...

AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...

The SEC announced last week that it had filed a complaint against Cassava Sciences, Inc., a “pharmaceutical company with one primary drug ...